JP2008509928A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008509928A5 JP2008509928A5 JP2007525838A JP2007525838A JP2008509928A5 JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5 JP 2007525838 A JP2007525838 A JP 2007525838A JP 2007525838 A JP2007525838 A JP 2007525838A JP 2008509928 A5 JP2008509928 A5 JP 2008509928A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- methylene
- tetraazacyclotetradecanyl
- phenylenebis
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000130 stem cell Anatomy 0.000 claims 13
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims 8
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims 8
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 7
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims 7
- 210000001185 bone marrow Anatomy 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 210000005259 peripheral blood Anatomy 0.000 claims 5
- 239000011886 peripheral blood Substances 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229920000768 polyamine Polymers 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 238000011124 ex vivo culture Methods 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 claims 1
- TWTLJZJKDUYSON-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CN=C1 TWTLJZJKDUYSON-UHFFFAOYSA-N 0.000 claims 1
- RTHCDPLDSUOFCC-UHFFFAOYSA-N n-(pyridin-4-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=NC=CC=1CNCC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 RTHCDPLDSUOFCC-UHFFFAOYSA-N 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60136704P | 2004-08-13 | 2004-08-13 | |
| PCT/US2005/028783 WO2006020891A2 (en) | 2004-08-13 | 2005-08-11 | Chemokine combinations to mobilize progenitor/stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509928A JP2008509928A (ja) | 2008-04-03 |
| JP2008509928A5 true JP2008509928A5 (cg-RX-API-DMAC7.html) | 2008-10-09 |
Family
ID=35908186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525838A Withdrawn JP2008509928A (ja) | 2004-08-13 | 2005-08-11 | 前駆／幹細胞を動員するためのケモカインの組み合わせ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060035829A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1796716A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008509928A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101094684A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005272653A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0514343A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2577046A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200608991A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006020891A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8435939B2 (en) * | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
| WO2007022523A2 (en) * | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
| MX2008010895A (es) * | 2006-02-24 | 2008-09-03 | Genzyme Corp | Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos. |
| WO2007132846A1 (ja) | 2006-05-16 | 2007-11-22 | Ono Pharmaceutical Co., Ltd. | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
| EP2068868A2 (en) * | 2006-08-02 | 2009-06-17 | Genzyme Corporation | Combination therapy |
| WO2008075370A2 (en) * | 2006-12-21 | 2008-06-26 | Biokine Therapeutics Ltd. | T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy |
| US9427456B2 (en) | 2009-06-14 | 2016-08-30 | Biokine Therapeutics Ltd. | Peptide therapy for increasing platelet levels |
| US20150030561A1 (en) | 2011-05-16 | 2015-01-29 | Genzyme Corp. | Use of CXCR4 Antagonists |
| CN103159690B (zh) * | 2011-12-14 | 2015-03-25 | 朱靖华 | 对称大环胺化合物的结晶形式 |
| WO2013160895A1 (en) | 2012-04-24 | 2013-10-31 | Biokine Therapeutics Ltd. | Peptides and use thereof in the treatment of large cell lung cancer |
| KR102083046B1 (ko) | 2012-06-07 | 2020-02-28 | 칠드런＇스 하스피틀 로스 앤젤레스 | 레티노이드 작용제를 이용하여 호중구감소증을 치료하기 위한 방법 |
| SG10201706858XA (en) * | 2013-02-28 | 2017-09-28 | Harvard College | Methods and compositions for mobilizing stem cells |
| AU2015219038B2 (en) | 2014-02-18 | 2018-10-18 | Children's Hospital Los Angeles | Compositions and methods for treating neutropenia |
| CA3026154A1 (en) * | 2015-06-03 | 2016-12-08 | The University Of Queensland | Mobilizing agents and uses therefor |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| EP3419645B1 (en) | 2016-02-23 | 2020-09-02 | BioLineRx Ltd. | Method of selecting a treatment regimen in acute myeloid leukemia (aml) |
| US20190060366A1 (en) * | 2016-02-26 | 2019-02-28 | President And Fellows Of Harvard College | Highly engraftable hematopoietic stem cells |
| WO2018085574A2 (en) * | 2016-11-02 | 2018-05-11 | Washington University | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof |
| IL293956A (en) | 2017-04-12 | 2022-08-01 | Magenta Therapeutics Inc | Aryl hydrocarbon receptor antagonist and its uses |
| US20190343885A1 (en) | 2017-10-31 | 2019-11-14 | Magenta Therapeutics Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
| CA3079405A1 (en) | 2017-10-31 | 2019-05-09 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| SG11202004913TA (en) * | 2017-12-06 | 2020-06-29 | Magenta Therapeutics Inc | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
| US20200338132A1 (en) | 2018-01-03 | 2020-10-29 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| WO2021087406A1 (en) | 2019-11-01 | 2021-05-06 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
| CN115997009A (zh) | 2020-04-27 | 2023-04-21 | 美真达治疗公司 | 用于在体内转导造血干细胞和祖细胞的方法和组合物 |
| WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
| CN116789639A (zh) * | 2022-03-14 | 2023-09-22 | 上海医药工业研究院有限公司 | Mavorixafor的纯化方法、其盐及有关物质 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680174A (en) * | 1984-05-24 | 1987-07-14 | Damon Biotech, Inc. | Induction of immune response by immunization with encapsulated antigen-producing cells |
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| DK0713495T3 (da) * | 1993-06-08 | 2004-03-08 | Smithkline Beecham Corp | Fremgangsmåder til forstærkning af den biologiske aktivitet af chemokiner |
| DE4320478B4 (de) * | 1993-06-21 | 2007-11-15 | Robert Bosch Gmbh | Fahrstabilitätsregler |
| CA2178902A1 (en) * | 1993-12-14 | 1995-06-22 | Drew Pardoll | Controlled release of pharmaceutically active substances for immunotherapy |
| GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US6713052B1 (en) * | 1995-10-24 | 2004-03-30 | Human Genome Sciences, Inc. | Method of mobilizing stem cells with chemokine β-8 |
| EP1016726A1 (en) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| JP2003516984A (ja) * | 1999-12-17 | 2003-05-20 | アノーメッド・インコーポレイテッド | ケモカインレセプターを結合する複素環式化合物 |
| WO2002022599A2 (en) * | 2000-09-15 | 2002-03-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| CA2421796A1 (en) * | 2000-09-15 | 2002-05-02 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| TR200300322T2 (tr) * | 2000-09-15 | 2003-09-22 | Anormed Inc. | Kemokin alıcısını bağlayan heterosiklik bileşikler |
| PL359292A1 (en) * | 2000-09-29 | 2004-08-23 | Anormed Inc. | Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof |
| CA2443685A1 (en) * | 2001-04-03 | 2002-10-17 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| AU2002318927B2 (en) * | 2001-07-31 | 2007-01-04 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| JP2005511049A (ja) * | 2001-12-07 | 2005-04-28 | トゥールゲン・インコーポレイテッド | キメラタンパク質の表現型スクリーニング |
| EP1613613B1 (en) * | 2003-04-11 | 2021-06-02 | Genzyme Corporation | Cxcr4 chemokine receptor binding compounds |
| BRPI0409655B8 (pt) * | 2003-04-22 | 2021-05-25 | Anormed Inc | compostos heterocíclicos de ligação ao receptor para quimiocina com maior eficiência |
| EP1708703A4 (en) * | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
-
2005
- 2005-08-11 AU AU2005272653A patent/AU2005272653A1/en not_active Abandoned
- 2005-08-11 WO PCT/US2005/028783 patent/WO2006020891A2/en not_active Ceased
- 2005-08-11 BR BRPI0514343-8A patent/BRPI0514343A/pt not_active IP Right Cessation
- 2005-08-11 JP JP2007525838A patent/JP2008509928A/ja not_active Withdrawn
- 2005-08-11 US US11/202,482 patent/US20060035829A1/en not_active Abandoned
- 2005-08-11 CA CA002577046A patent/CA2577046A1/en not_active Abandoned
- 2005-08-11 EP EP05788603A patent/EP1796716A4/en not_active Withdrawn
- 2005-08-11 CN CNA2005800323327A patent/CN101094684A/zh active Pending
- 2005-08-12 TW TW094127548A patent/TW200608991A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509928A5 (cg-RX-API-DMAC7.html) | ||
| US20230167076A1 (en) | 1,2,4-Oxadiazole Derivatives as Immunomodulators | |
| CA2455559A1 (en) | Methods to mobilize progenitor/stem cells | |
| ES2983582T3 (es) | Composiciones bioortogonales | |
| JP2014513727A5 (cg-RX-API-DMAC7.html) | ||
| JP2008528658A5 (cg-RX-API-DMAC7.html) | ||
| JP2008195730A5 (cg-RX-API-DMAC7.html) | ||
| JP2017533922A5 (cg-RX-API-DMAC7.html) | ||
| JP2014528467A5 (cg-RX-API-DMAC7.html) | ||
| JP2016505586A5 (cg-RX-API-DMAC7.html) | ||
| JP2011006428A5 (cg-RX-API-DMAC7.html) | ||
| CA2361587A1 (en) | Methods and compositions to enhance white blood cell count | |
| RU2010113982A (ru) | Применение пептида в качестве терапевтического средства | |
| JP2022095872A5 (cg-RX-API-DMAC7.html) | ||
| CN101495115A (zh) | 组合治疗 | |
| RU2006132071A (ru) | Производные антраниловой кислоты, способы их получения и применение | |
| US20240158445A1 (en) | Cyclic cell-penetrating peptides with three or more hydrophobic residues | |
| TW200607508A (en) | Powder formulations for inhalation, comprising enantiomerically pure beta agonists | |
| CN101175490B (zh) | 循环障碍改善剂 | |
| JP2008520682A (ja) | ヒストンデアセチラーゼ阻害剤およびその使用方法 | |
| EP1345604B1 (en) | Use of a alpha-halogen-acryloyl distamycin derivate for the preparation of a medicament for the treatment of cancer | |
| JP2005527479A5 (cg-RX-API-DMAC7.html) | ||
| ES2547726T3 (es) | Nueva enzima altamente funcional que tiene especificidad de sustrato modificada | |
| WO2008113095A1 (en) | Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb) | |
| CA2954175A1 (en) | Compositions and methods to improve adoptive cell therapies |